Limitations of Targeted Cancer Therapies in Pancreatic Ductal Adenocarcinoma
Photo by Hush Naidoo Jade on Unsplash.com
By: Riyana Bhatt
Abstract
Targeted cancer therapies are designed to explore distinct molecular characterizations unique to tumor cells, allowing precise tumor elimination with minimal harm to normal, healthy tissues. However, pancreatic ductal adenocarcinoma, the most common subset of pancreatic cancers and a leading cause of cancer-related deaths, remains a prominent example of how this design falls short in application. Although select subpopulations of PDAC patients, such as those with BRCA1/2, PALB2 mutations, or rare KRAS-wild-type rearrangements, can potentially benefit from PARP inhibiting agents or KRAS-directed therapies, successful outcomes have been rare. This report aims to investigate why targeted therapies rarely provide a true “cure” to PDAC. Evidence suggests two major barriers: extreme tumor heterogeneity arising from complex genetic drivers and a uniquely dense, immunosuppressive tumor microenvironment that limits drug penetration and hinders immune-based strategies. By integrating findings from molecular profiling studies, clinical trials, and investigations into PDAC progression, this report examines why targeted agents of PDAC have had minimal impact compared to other solid tumors. Understanding these limitations may guide the development of better therapeutics better suited to overcome PDAC’s resistance mechanisms.
Background, Research Question and Hypothesis
Background
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest forms of cancer, with a 5-year survival rate below 10% and a median survival of only a few months in advanced disease (Yasinzai et al., 2024). Its aggressive clinical course is shaped by a poor combination of genetic alterations and its distinct suppressive tumor microenvironment, making PDAC far less responsive to modern cancer therapeutics compared to other solid tumors.
More than 90% of PDAC cases are a result of activated mutations in KRAS, along with frequent loss of tumor suppressors such as CDKN2A and TP53, contributing to genomic instability, uncontrolled proliferation, and resistance to cell death (Ferrone et al., 2012). Additionally, PDAC tumors exhibit a dense desmoplastic stroma, consisting of fibroblasts, extracellular matrix proteins, and immunosuppressive cell populations, that account for up to 90% of total tumor volume and physically obstruct drug delivery (Shalaby et al., 2025). These biological characteristics make PDAC exceptionally difficult to treat and have limited the success of both cytotoxic and targeted therapies.
Research Question
This raises the question, why are targeted cancer therapies rarely effective in patients with pancreatic ductal adenocarcinoma? Given these perpetual challenges, it is essential to investigate why PDAC has not benefited from targeted therapies that are effective in other solid tumors. Understanding the biological and microenvironmental barriers to treatment may help clarify these PDAC-specific differences and guide future therapeutic development.
Justification
Although targeted therapies have significantly improved outcomes in several other cancers, their impact on PDAC has been minimal. The only FDA-approved targeted therapy for PDAC, erlotinib, provides a mean survival benefit of a mere two weeks when combined with gemcitabine, highlighting the current limited clinical efficacy (Narayanan & Weekes, 2016). More recently, targeted treatments such as PARP inhibitors for BRCA1/2- or PALB2-mutated tumors and novel KRAS G12C inhibitors have shown potential in few PDAC subsets with targetable genomic profiles (Li et al., 2024). However, persistent responses remain limited, and only a very small percentage of PDAC patients possess these genetic alterations (Li et al., 2024). Immunotherapies, including PD-1/PD-L1 inhibitors that have provided positive outcomes in melanoma, lung cancer, and other malignancies, have similarly failed in PDAC, likely due to its immunologically unresponsive and poorly infiltrated T-cell microenvironment (Ramesh et al., 2025).
Hypothesis
Ultimately, research suggests that target therapies fail to produce successful outcomes in PDAC due to its extreme tumor heterogeneity arising from complex genetic drivers that promote therapeutic resistance, and its dense, immunosuppressive tumor microenvironment that restricts drug penetration and prevents effective immune activation.
Results, Data and Evidence
First, targeted PARP inhibitors, such as olaparib, have been evaluated in PDAC patients with BRCA1/2 or PALB2 mutations. The POLO trial randomized patients with germline BRCA-mutated metastatic PDAC to receive either olaparib therapy or a placebo (Golan et al., 2019). Olaparib significantly improved progression-free survival, with a median of 7.4 months compared to 3.8 months for the placebo, but overall survival benefits were not statistically significant. Figure 2 from the POLO trial demonstrates that while olaparib delayed disease progression, the survival curve did not plateau, indicating that most patients eventually experienced disease progression (Golan et al., 2019). This evidence supports the notion that even molecularly targeted therapies tailored to specific genetic variations are minimally effective in PDAC.
Figure 1. Kaplan-Meier Estimates of Progression-free Survival and Overall Survival (Golan et al., 2019)
Second, KRAS-directed therapies are a promising subset of targeted agents in PDAC. KRAS mutations are present in over 90% of tumors, but until recently, these mutations were considered to be untreatable. Sotorasib, a KRAS G12C inhibitor, has shown clinical activity in early-phase trials (Bekaii-Saab et al., 2023). Response rates are relatively promising, with approximately 10-20% of patients showing partial responses. Figure 1 of the efficacy analyses of sotorasib therapy quantifies individual patient responses, duration of treatment, and the best percentage change in tumor burden from baseline (Strickler et al., 2022). This figure highlights that only a small subset of patients achieve significant tumor reduction, while many experience disease progression despite intervention. Panels C and D provide Kaplan-Meier curves of progression-free and overall survival, respectively, showing that although sotorasib can delay disease progression, the majority of patients eventually relapse (Strickler et al., 2022). The minimal number of responders illustrates the challenge of extreme tumor heterogeneity in PDAC, as subclonal populations lacking KRAS G12C mutations can bypass inhibition, reducing long-term treatment efficacy. Collectively, these findings emphasize why even genetically targeted agents like KRAS inhibitors are ineffective.
Figure 2. Efficacy Analyses of Sotorasib Therapy (Strickler et al., 2022)
Third, immunotherapy outcomes in PDAC have been disappointing. Checkpoint inhibitors targeting PD-1/PD-L1, which have shown remarkable success in melanoma and lung cancer, have shown deficiencies in most PDAC patients. Response rates in clinical trials of pembrolizumab for mismatch repair-deficient PDAC remain below 10%, with long-term survival observed only in rare cases (Ye et al., 2024). Figure 1 of immune-checkpoint based treatment options explores the current landscape of clinical immunotherapy strategies for pancreatic cancer, including monotherapies such as immune checkpoint inhibitors, tumor-targeting antibodies, tumor vaccines, and CAR T-cell therapies, as well as combination approaches with chemotherapy or radiotherapy (Ye et al., 2024). This figure highlights that while numerous immunotherapeutic approaches have been tested, most have shown minimal clinical efficacy in PDAC. The dense stroma, immunosuppressive immune cell populations, and poor T-cell infiltration collectively create a tumor microenvironment that limits the effectiveness of these therapies (Ye et al., 2024). This reinforces the conclusion that PDAC’s unique microenvironment is a key barrier of prospective immunotherapies.
Figure 3. Current clinical immunotherapy strategies for pancreatic cancer (Ye et al., 2024)
In addition to clinical trial evidence, genomic profiling studies from The Cancer Genome Atlas (TCGA) highlight the extreme heterogeneity of PDAC tumors. Frequent alterations in KRAS, TP53, CDKN2A, and SMAD4 partner with less common but targetable mutations, such as BRAF, NTRK, and ALK rearrangements (Initiative et al., 2015). These mutations illustrate why targeting a single molecular pathway often fails to eliminate the disease entirely.
Collectively, such evidence demonstrates that while targeted therapies can irregularly provide clinical benefit to selected patients, extreme tumor heterogeneity and the immunosuppressive microenvironment of PDAC severely limits these interventions.
Discussion and Conclusion
Overall, the evidence demonstrates that targeted therapies in PDAC face demanding barriers. Although interventions such as PARP inhibitors, KRAS G12C inhibitors, and emerging immunotherapies have been explored, benefits are often temporary and limited to a small fraction of patients.
This report supports the central hypothesis that PDAC’s extensive tumor heterogeneity and immunosuppressive microenvironment undermine nearly every targeted intervention. Even when a therapy precisely matches a patient’s genetic alteration, coinciding survival pathways, stromal shielding, poor immune infiltration, and rapid adaptive resistance prevent a successful intervention in PDAC.
The broader implication is that future therapeutic development will depend on approaches capable of addressing multiple resistance mechanisms simultaneously. This could include combinations of therapies that pair targeted inhibitors with those that remodel the stroma or enhance immune infiltration. Additionally, continued genomic profiling will be critical to further define which patients are most likely to benefit from each therapeutic approach allowing for specialized interventions.
In conclusion, targeted therapies currently remain insufficient “cures” for PDAC on their own. Focus toward combinational and genetically-specialized strategies offers the most promising path of treating PDAC. By understanding the limits of current therapies, the field is better positioned to design future interventions that can finally overcome PDAC’s unique resistance.
Bibliography
Bekaii-Saab TS, Yaeger R, Spira AI, Pelster MS, Sabari JK, Hafez N, Barve M, Velastegui K, Yan X, Shetty A, Der-Torossian H, Pant S. Adagrasib in Advanced Solid Tumors Harboring a KRASG12CMutation. J Clin Oncol. 2023 Sep 1;41(25):4097-4106. doi: 10.1200/JCO.23.00434.
Ferrone CR, Pieretti-Vanmarcke R, Bloom JP, Zheng H, Szymonifka J, Wargo JA, Thayer SP, Lauwers GY, Deshpande V, Mino-Kenudson M, Fernández-del Castillo C, Lillemoe KD, Warshaw AL. Pancreatic ductal adenocarcinoma: long-term survival does not equal cure. Surgery. 2012 Sep;152(3 Suppl 1):S43-9. doi: 10.1016/j.surg.2012.05.020.
Golan T, Hammel P, Reni M, Van Cutsem E, Macarulla T, Hall MJ, Park JO, Hochhauser D, Arnold D, Oh DY, Reinacher-Schick A, Tortora G, Algül H, O’Reilly EM, McGuinness D, Cui KY, Schlienger K, Locker GY, Kindler HL. Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. N Engl J Med. 2019 Jul 25;381(4):317-327. doi: 10.1056/NEJMoa1903387.
Initiative, A. P. C. G., Waddell, N., Pajic, M., Patch, A., Chang, D. K., Kassahn, K. S., Bailey, P., Johns, A. L., Miller, D., Nones, K., Quek, K., Quinn, M. C. J., Robertson, A. J., Fadlullah, M. Z. H., Bruxner, T. J. C., Christ, A. N., Harliwong, I., Idrisoglu, S., Manning, S., . . . Grimmond, S. M. (2015). Whole genomes redefine the mutational landscape of pancreatic cancer. Nature, 518(7540), 495–501. https://doi.org/10.1038/nature14169
Li B, Zhang Q, Castaneda C, Cook S. Targeted Therapies in Pancreatic Cancer: A New Era of Precision Medicine. Biomedicines. 2024 Sep 25;12(10):2175. doi: 10.3390/biomedicines12102175.
Narayanan V, Weekes CD. Molecular therapeutics in pancreas cancer. World J Gastrointest Oncol. 2016 Apr 15;8(4):366-79. doi: 10.4251/wjgo.v8.i4.366.
Ramesh RPG, Yasmin H, Ponnachan P, Al-Ramadi B, Kishore U, Joseph AM. Phenotypic heterogeneity and tumor immune microenvironment directed therapeutic strategies in pancreatic ductal adenocarcinoma. Front Immunol. 2025 Mar 31;16:1573522. doi: 10.3389/fimmu.2025.1573522.
Shalaby A, Sadri N, Xue Y. Molecular Pathology of Pancreatic Ductal Adenocarcinoma. Cancers (Basel). 2025 Nov 2;17(21):3549. doi: 10.3390/cancers17213549.
Strickler JH, Satake H, George TJ, Yaeger R, Hollebecque A, Garrido-Laguna I, Schuler M, Burns TF, Coveler AL, Falchook GS, Vincent M, Sunakawa Y, Dahan L, Bajor D, Rha SY, Lemech C, Juric D, Rehn M, Ngarmchamnanrith G, Jafarinasabian P, Tran Q, Hong DS. Sotorasib in KRAS p.G12C-Mutated Advanced Pancreatic Cancer. N Engl J Med. 2023 Jan 5;388(1):33-43. doi: 10.1056/NEJMoa2208470.
Yasinzai AQK, Tareen B, Tracy K, Jamil N, Khan M, Ullah H, Raza M, Khan AU, Arif D, Waheed A, Sidhwa F, Misra S, Karki NR, Karim NA, Cavalcante L, Ullah A. Pancreatic ductal adenocarcinoma: exploring clinicopathological trends and racial disparities in a comprehensive U.S. population-based study. Clin Transl Oncol. 2024 Oct;26(10):2618-2628. doi: 10.1007/s12094-024-03484-7.
Ye X, Yu Y, Zheng X, Ma H. Clinical immunotherapy in pancreatic cancer. Cancer Immunol Immunother. 2024 Mar 2;73(4):64. doi: 10.1007/s00262-024-03632-6.